PMID- 16730260
OWN - NLM
STAT- MEDLINE
DCOM- 20090528
LR  - 20220409
IS  - 0065-2776 (Print)
IS  - 0065-2776 (Linking)
VI  - 90
DP  - 2006
TI  - Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing 
      tumor development and shaping tumor immunogenicity.
PG  - 1-50
AB  - Cellular transformation and tumor development result from an accumulation of 
      mutational and epigenetic changes that alter normal cell growth and survival 
      pathways. For the last 100 years, there has been a vigorous debate as to whether 
      the unmanipulated immune system can detect and eliminate such altered host 
      derived cells despite the fact that cancer cells frequently express either 
      abnormal proteins or abnormal levels of normal cellular proteins that function as 
      tumor antigens. In this review, we discuss the current state of this argument and 
      point out some of the recent key experiments demonstrating that immunity not only 
      protects the host from cancer development (i.e., provides a cancer 
      immunosurveillance function) but also can promote tumor growth, sometimes by 
      generating more aggressive tumors. The terminology "cancer immunoediting" has 
      been used to describe this dual host protective and tumor promoting action of 
      immunity, and herein we summarize the ever-increasing experimental and clinical 
      data that support the validity of this concept.
FAU - Smyth, Mark J
AU  - Smyth MJ
AD  - Cancer Immunology Program, Peter MacCallum Cancer Centre, East Melbourne, 3002 
      Victoria, Australia.
FAU - Dunn, Gavin P
AU  - Dunn GP
FAU - Schreiber, Robert D
AU  - Schreiber RD
LA  - eng
GR  - CA 106377/CA/NCI NIH HHS/United States
GR  - CA 107527/CA/NCI NIH HHS/United States
GR  - CA 43059/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Adv Immunol
JT  - Advances in immunology
JID - 0370425
SB  - IM
MH  - Animals
MH  - Humans
MH  - Immunity, Cellular/*immunology
MH  - Immunity, Innate/*immunology
MH  - *Immunosuppression Therapy/methods/trends
MH  - Monitoring, Immunologic/*methods/*trends
MH  - Neoplasms/*immunology/metabolism/pathology/*prevention & control
MH  - Neoplasms, Experimental/immunology/metabolism/pathology/therapy
RF  - 276
EDAT- 2006/05/30 09:00
MHDA- 2009/05/29 09:00
CRDT- 2006/05/30 09:00
PHST- 2006/05/30 09:00 [pubmed]
PHST- 2009/05/29 09:00 [medline]
PHST- 2006/05/30 09:00 [entrez]
AID - S0065-2776(06)90001-7 [pii]
AID - 10.1016/S0065-2776(06)90001-7 [doi]
PST - ppublish
SO  - Adv Immunol. 2006;90:1-50. doi: 10.1016/S0065-2776(06)90001-7.